BruceRobertBlazarMD
Pediatric Hematology & Oncology • Minneapolis, MNRegents Professor, Pediatrics, University of Minnesota Medical School
Are you Dr. Blazar?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 92 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
516 Delaware Street SE
University of MN Physicians PWB Fifth floor Clinic 5B
Minneapolis, MN 55455Phone+1 612-273-2800Fax+1 612-626-4074
Summary
- Dr. Bruce Blazar, MD is a pediatric hematologist/oncologist in Minneapolis, Minnesota. He is currently licensed to practice medicine in Minnesota. He is affiliated with M Health Fairview Masonic Children’s Hospital and M Health Fairview University of Minnesota Medical Center.
Education & Training
University of MinnesotaFellowship, Pediatric Hematology/Oncology, 1982 - 1985- University of MinnesotaResidency, Pediatrics, 1978 - 1981
Albany Medical CollegeClass of 1978
Certifications & Licensure
MN State Medical License 1980 - 2025- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1996
Publications & Presentations
PubMed
- Regulatory T cells crosstalk with tumor cells and endothelium through lymphotoxin signaling.Wenji Piao, Long Wu, Yanbao Xiong, Gregory C Zapas, Christina M Paluskievicz
Nature Communications. 2024-12-02 - 2 citationsTwin Prime Editing Mediated Exon Skipping/Reinsertion for Restored Collagen VII Expression in Recessive Dystrophic Epidermolysis Bullosa.Benjamin J Steinbeck, Xin D Gao, Amber N McElroy, Smriti Pandey, Jordan L Doman
The Journal of Investigative Dermatology. 2024-12-01 - JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results.Joseph Pidala, Shernan G Holtan, Kelly Walton, Jongphil Kim, Biwei Cao
Blood. 2024-11-28
Press Mentions
CARISMA Therapeutics Establishes Collaboration with Leading Cell Therapy Expert to Explore and Develop Allogeneic CAR-MacrophagesApril 26th, 2021- Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at the American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020
BlueRock Therapeutics Establishes Key Partnerships with Leading Experts in Autoimmune DiseaseJanuary 16th, 2019- Join now to see all
Grant Support
- Nontoxic Strategies To Establish Allochimerism In MiceNational Heart, Lung, And Blood Institute2004–2012
- University Of Minnesota Clinical And Translational Science Institute (Umn Ctsi)National Center For Research Resources2011
- CTSA Infrastructure For Pediatric ResearchNational Center For Research Resources2011
- CTSA Infrastructure For Clinical TrialsNational Center For Research Resources2011
- CTSA Infrastructure For AIDS ResearchNational Center For Research Resources2011
- T Progenitor And Thymic Epithelial Cell Replacement Post TransplantNational Cancer Institute2010–2011
- Molecular Mechanisms Of Thymic Epithelial Cell Involution In AgingNational Institute On Aging2009–2011
- Role Of Novel Inhibitory Pathways In Alloimmunity And ToleranceNational Institute Of Allergy And Infectious Diseases2009–2011
- Mouse Models Of Chronic Graft-Vs-Host DiseaseNational Cancer Institute2009–2011
- Cytotoxic-T-Lymphocyte (CTL) Therapy Of AMLNational Cancer Institute2007–2011
- T Cell Targeting For GVHDNational Heart, Lung, And Blood Institute1998–2011
- In Vivo Prevention Of Murine GVHDNational Institute Of Allergy And Infectious Diseases1997–2011
- Cellular Approaches To Reduce BMT ComplicationsNational Heart, Lung, And Blood Institute2005–2008
- Post BMT Lung Injury PathophysiologyNational Heart, Lung, And Blood Institute2000–2008
- T Cell Targeting For GVHDNational Heart, Lung, And Blood Institute1998–2007
- Strategies To Prevent And Repair Thymic MicroenvironmentNational Heart, Lung, And Blood Institute2003–2006
- GVL To Reduce AML Relapse After Murine Allogeneic BMTNational Cancer Institute1997–2006
- Correction Of Murine Immunodeficiencies In UteroNational Heart, Lung, And Blood Institute1994–2005
- In Utero Transfer Of Hematopoietic CellsNational Heart, Lung, And Blood Institute2000–2004
- Nontoxic Strategies To Establish AllochimerismNational Heart, Lung, And Blood Institute1999–2002
- Research Training In BMT Biology As Related To CancerNational Cancer Institute1996–2000
- In Utero Transfer Of Murine Hematopoietic CellsNational Heart, Lung, And Blood Institute1997–1998
- Post Bone Marrow Transplant Lung Injury PathophysiologyNational Heart, Lung, And Blood Institute1995–1998
- Liver RejectionNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1997
- Retroviral Transduction Of Lymphocytes For Anti-Lymphoma TherapyNational Cancer Institute1996–1997
- T-Cell Targeting For GVHDNational Heart, Lung, And Blood Institute1995–1997
- In Utero Transfer Of Murine Hematopoietic Cells In MiceNational Heart, Lung, And Blood Institute1994–1996
- In Vivo Prevention Of Murine Graft-Versus-Host DiseaseNational Institute Of Allergy And Infectious Diseases1993–1996
- Factors Affecting Marrow EngraftmentNational Institute Of Diabetes And Digestive And Kidney Diseases1989
- Factors Affecting Marrow Engraftment In Man And MouseNational Institute Of Diabetes And Digestive And Kidney Diseases1986–1988
- Factors Affecting Marrow Engraftment In Man And MouseNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985
